The Act provides incentives for pharmaceutical manufacturers to develop drugs, biotechnology products, and medical devices for the treatment of rare diseases and conditions. These products are commonly referred to as orphan products. Incentives for orphan product development include marketing exclusivity for orphan drug sponsors, tax incentives, and research grants. See more ». This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks.
By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies. Kimberlynn Davis Ph. To embed, copy and paste the code into your website or blog:. Overview of the Orphan Drug Act In a time defined by a hyper-focus on a single disease affecting millions of people across the country, it can be easy to lose sight of the many other diseases that affect far fewer Americans.
Send Print Report. April Abele Isaacson. Akkad Moussa. Published In: Biden Administration. PLoS Med. Incentives for orphan drug research and development in the United States. Orphanet J Rare Dis. Kesselheim AS. An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences. Milbank Q. Institute for Value-Based Medicine.
About AJMC. January 4, Laura Joszt, MA.
0コメント